COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Food and Drug Administration June 25 formally updated its patient and provider fact sheets for the Moderna and Pfizer COVID-19 vaccines to include warnings about the increased risk of heart inflammation in patients.
The Food and Drug Administration authorized for emergency use a new drug to treat hospitalized patients receiving systemic corticosteroids who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation.
The Centers for Disease Control and Prevention awarded states and other jurisdictions $200 million in supplemental funding from the American Rescue Plan Act to hire and train disease intervention specialists to prevent and respond to COVID-19 and other infectious diseases.
The Centers for Disease Control and Prevention updated requirements for health care providers participating in the COVID-19 Vaccination Program to clarify that participants may not sell or divert COVID-19 vaccine or ancillary materials purchased for the program; reproduce the program’s COVID-19…
The Food and Drug Administration authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore.
As requested by the AHA, the Centers for Medicare & Medicaid Services said it will continue to remain flexible in its approach to surveys if a hospital experiences a COVID-19 surge.
CMS to take flexible approach to survey process if hospital experiences COVID-19 surge.
The Centers for Disease Control and Prevention released a COVID-19 Viral Testing Tool to help health care providers and individuals understand their COVID-19 testing options and take appropriate next steps.
Only 11% of pregnant women in the Centers for Disease Control and Prevention’s Vaccine Safety Datalink, which includes vaccine safety monitoring data from nine integrated health systems, were fully vaccinated against COVID-19 by May 8, compared with 25% of non-pregnant women, the CDC reported.
The Food and Drug Administration Friday authorized for emergency use two batches of drug substance manufactured for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore.